Assembly Actions -
Lowercase Senate Actions - UPPERCASE |
|
---|---|
Jan 24, 2014 |
print number 3270a |
Jan 24, 2014 |
amend and recommit to health |
Jan 08, 2014 |
referred to health |
Jan 31, 2013 |
referred to health |
Senate Bill S3270
2013-2014 Legislative Session
Sponsored By
(D, WF) 28th Senate District
Archive: Last Bill Status - In Senate Committee Health Committee
- Introduced
-
- In Committee Assembly
- In Committee Senate
-
- On Floor Calendar Assembly
- On Floor Calendar Senate
-
- Passed Assembly
- Passed Senate
- Delivered to Governor
- Signed By Governor
Actions
Bill Amendments
2013-S3270 - Details
- Current Committee:
- Senate Health
- Law Section:
- Public Health Law
- Laws Affected:
- Amd §206, Pub Health L; amd §§208 & 612, Tax L
- Versions Introduced in Other Legislative Sessions:
-
2011-2012:
S2855
2015-2016: S2625
2017-2018: S4001
2013-S3270 - Summary
Requires manufacturers and labelers of prescription drugs dispensed in this state which engage in marketing activities in the state to annually report marketing expenses to the department of health; imposes a $10,000 civil fine for failure to report; eliminates deductibility for certain expenses incurred in the advertising of prescription drugs.
2013-S3270 - Sponsor Memo
BILL NUMBER:S3270 TITLE OF BILL: An act to amend the public health law, in relation to requiring the manufacturer or labeler of each prescription drug to annu- ally report the marketing costs of such drug to the department of health and to amend the tax law, in relation to eliminating deductibility for certain expenses incurred in the advertising of prescription drugs PURPOSE: To require manufacturers and labelers of prescription drugs dispensed in this state to annually report marketing expenses to the department of health and to eliminate certain tax deductions by pharma- ceutical companies for costs incurred for advertising. SUMMARY OF PROVISIONS: Section 1 sets forth the legislative intent of the bill. Section 2 of the bill amends section 206 of the public health law by adding a new subdivision 29. -Requiring the commissioner to collect marketing data and information from prescription drug manufacturers marketing their products in New York. -Sets forth definitions of terms used in the bill and sets forth the rules and requirements for reporting and establishes the different
2013-S3270 - Bill Text download pdf
S T A T E O F N E W Y O R K ________________________________________________________________________ 3270 2013-2014 Regular Sessions I N S E N A T E January 31, 2013 ___________ Introduced by Sen. KRUEGER -- read twice and ordered printed, and when printed to be committed to the Committee on Health AN ACT to amend the public health law, in relation to requiring the manufacturer or labeler of each prescription drug to annually report the marketing costs of such drug to the department of health and to amend the tax law, in relation to eliminating deductibility for certain expenses incurred in the advertising of prescription drugs THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM- BLY, DO ENACT AS FOLLOWS: Section 1. Legislative intent. The legislature hereby finds and declares that the price of prescription drugs in this state and across the nation has been increasing at an alarming rate over the past decade. Prescription drug costs are increasing at a faster rate than any other component of health care and are driving the increase in overall health care cost. As is apparent by the ubiquitous nature of the marketing and public information campaigns relating to prescription drugs, pharmaceu- tical manufacturers put a great deal of resources into marketing their products. This has been especially true since the 1997 relaxation of federal laws relating to prescription drug advertising. It is in the interest of assisting this state in its role as a purchaser of prescription drugs and administrator of prescription drug programs, to enable the state to determine the scope of prescription drug marketing costs and their effect on the cost, utilization and delivery of health care services, and thus further the role of this state as guardian of the public interest. S 2. Section 206 of the public health law is amended by adding a new subdivision 29 to read as follows: 29. THE COMMISSIONER IS AUTHORIZED AND DIRECTED TO REQUIRE MANUFACTUR- ERS OR LABELERS OF PRESCRIPTION DRUGS, WHICH DISPENSE SUCH DRUGS IN THIS STATE AND WHICH EMPLOY, DIRECT OR UTILIZE MARKETING REPRESENTATIVES IN EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets [ ] is old law to be omitted. LBD01521-01-3
2013-S3270A (ACTIVE) - Details
- Current Committee:
- Senate Health
- Law Section:
- Public Health Law
- Laws Affected:
- Amd §206, Pub Health L; amd §§208 & 612, Tax L
- Versions Introduced in Other Legislative Sessions:
-
2011-2012:
S2855
2015-2016: S2625
2017-2018: S4001
2013-S3270A (ACTIVE) - Summary
Requires manufacturers and labelers of prescription drugs dispensed in this state which engage in marketing activities in the state to annually report marketing expenses to the department of health; imposes a $10,000 civil fine for failure to report; eliminates deductibility for certain expenses incurred in the advertising of prescription drugs.
2013-S3270A (ACTIVE) - Sponsor Memo
BILL NUMBER:S3270A TITLE OF BILL: An act to amend the public health law, in relation to requiring the manufacturer or labeler of each prescription drug to annually report the marketing costs of such drug to the department of health and to amend the tax law, in relation to eliminating deductibility for certain expenses incurred in the advertising of prescription drugs PURPOSE: To require manufacturers and labelers of prescription drugs dispensed in this state to annually report marketing expenses to the department of health and to eliminate certain tax deductions by pharmaceutical companies for costs incurred for advertising. SUMMARY OF PROVISIONS: Section 1 sets forth the legislative intent of the bill. Section 2 of the bill amends section 206 of the public health law by adding a now subdivision 29. -Requiring the commissioner to collect marketing data and information from prescription drug manufacturers marketing their products in New York. -Sets forth definitions of terms used in the bill and sets forth the
2013-S3270A (ACTIVE) - Bill Text download pdf
S T A T E O F N E W Y O R K ________________________________________________________________________ 3270--A 2013-2014 Regular Sessions I N S E N A T E January 31, 2013 ___________ Introduced by Sen. KRUEGER -- read twice and ordered printed, and when printed to be committed to the Committee on Health -- recommitted to the Committee on Health in accordance with Senate Rule 6, sec. 8 -- committee discharged, bill amended, ordered reprinted as amended and recommitted to said committee AN ACT to amend the public health law, in relation to requiring the manufacturer or labeler of each prescription drug to annually report the marketing costs of such drug to the department of health and to amend the tax law, in relation to eliminating deductibility for certain expenses incurred in the advertising of prescription drugs THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM- BLY, DO ENACT AS FOLLOWS: Section 1. Legislative intent. The legislature hereby finds and declares that the price of prescription drugs in this state and across the nation has been increasing at an alarming rate over the past decade. Prescription drug costs are increasing at a faster rate than any other component of health care and are driving the increase in overall health care cost. As is apparent by the ubiquitous nature of the marketing and public information campaigns relating to prescription drugs, pharmaceu- tical manufacturers put a great deal of resources into marketing their products. This has been especially true since the 1997 relaxation of federal laws relating to prescription drug advertising. It is in the interest of assisting this state in its role as a purchaser of prescription drugs and administrator of prescription drug programs, to enable the state to determine the scope of prescription drug marketing costs and their effect on the cost, utilization and delivery of health care services, and thus further the role of this state as guardian of the public interest. S 2. Section 206 of the public health law is amended by adding a new subdivision 29 to read as follows: EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets [ ] is old law to be omitted. LBD01521-02-4
Comments
Open Legislation is a forum for New York State legislation. All comments are subject to review and community moderation is encouraged.
Comments deemed off-topic, commercial, campaign-related, self-promotional; or that contain profanity, hate or toxic speech; or that link to sites outside of the nysenate.gov domain are not permitted, and will not be published. Attempts to intimidate and silence contributors or deliberately deceive the public, including excessive or extraneous posting/posts, or coordinated activity, are prohibited and may result in the temporary or permanent banning of the user. Comment moderation is generally performed Monday through Friday. By contributing or voting you agree to the Terms of Participation and verify you are over 13.
Create an account. An account allows you to sign petitions with a single click, officially support or oppose key legislation, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.